Active infection that requires systemic treatment
Subject has an active infection
Patients with a clinically apparent active infection will not be eligible (please note, an isolated elevation in the white blood cell count, by itself, does not constitute evidence of an infection)
Active infection
Has an active systemic infection
Active infection
Active serious infection
Active infection not adequately responding to appropriate therapy
Active infection
Evidence of active infection
Patients with active infection
Recent (< 4 weeks) active, documented, cervical infection
Patients with active infection
Active infection of any kind.
DONOR: Evidence of active infection
No active or uncontrollable infection.
Active infection
Active infection or corneal ulcer (e.g. keratitis)
Active or incompletely treated local infection at the planned treatment site(s) and/or systemic infection
Active uncontrolled infection or severe systemic infection (enrollment is possible after control of infection).
Active infection, including any active viral infection, =< 5 days prior to registration
DONOR: Active infection
Patients with active systemic, pulmonary, or pericardial infection
Active infection
Active infection or corneal ulcer
DONOR: Active infection
Active infection
Ongoing or active systemic infection or active hepatitis B or C virus infection
No active or uncontrollable infection
HIV infection, active Hepatitis B or C infection, or active infections requiring oral or intravenous antibiotics or that can cause a severe disease and pose a severe danger to lab personnel working on patients' blood or tissue. If positive test results are not indicative of an active infection, patients can be included.
Active infection
Active infection not adequately responding to appropriate therapy
Active infection =< 5 days prior to registration
Active systemic, pulmonary, or pericardial infection
Patients with active infection
Active infection
DONOR: Evidence of active infection
Active infection not responding to appropriate therapy as determined by study chair
Active infection that is not responding to antimicrobial therapy
TREATMENT: Patients with severe active infection
No evidence of active infection and no serious infection within the past month
Evidence of active infection, or serious infection within the past month
No evidence of active infection and no serious infection within the past month
Evidence of active infection, or serious infection within the past month
Active herpes zoster infection
Active infection =< 5 days prior to registration
Patients with active infection
No active infection
Evidence of active infection or serious infection within the past month
RECIPIENT: Active infection refractory to antimicrobial therapy
Active systemic infection
No evidence of active infection and no serious infection within the past month
Evidence of active infection, or serious infection within the past month
Active infection
Active and uncontrolled infection at time of transplantation including active infection with Aspergillus or other mold, or human immunodeficiency virus (HIV) infection
Active systemic, pulmonary, or pericardial infection
Active infection that is not responding to antimicrobial therapy
Active infection at time of transplantation (including active infection with Aspergillus or other mold within 30 days)
Active infection at time of transplantation (including active infection with aspergillus or other mold within 30 days)
Current active serious infection
Patients with active systemic, pulmonary, or pericardial infection
Serious active infection
Active infection.
Patients with an active infection
Subjects with bacteremia with documented microbiological evidence of another source of infection (eg, osteomyelitis, pneumonia, skin infection, urinary tract infection, joint infection, or abdominal infection) known to be due to the same organism cultured from the blood;
Active infection, chronic or severe infection requiring ongoing antimicrobial therapy.
Evidence of active infection, or serious infection within the past month
Active infection
Active infection =< 5 days prior to registration
Active infection at time of transplantation (including active infection with Aspergillus or other mold within 30 days)
Active infection
Active infection not adequately responding to appropriate therapy.
Patients with active infection are ineligible
Active infection =< 5 days prior to registration
Active serious infection
Patient may have no active uncontrollable systemic infection
Active ear/sinus infection
Patients with active infection
Subjects with an active infection
Active infection that is not responding to antimicrobial therapy
They have active diarhhea.
Active infection
Active infection
Active, unresolved infection
Active infection or corneal ulcer (e.g., keratitis)
Evidence of active infection within 2 weeks prior to first dose of study treatment.
Patients are ineligible if they have an active infection
Active infection;
Active infection not adequately responding to appropriate therapy.
Active infection (any infection requiring treatment).
Infection
Patients with an active infection.
No active systemic, pulmonary, or pericardial infection
Current systemic infection or suspicion of active bacterial infection
Active infection
Active and uncontrolled infection; patients with an active infection receiving treatment and hemodynamically stable for 48 hours may be entered into the study
Patient has evidence of active systemic, pulmonary, or pericardial infection.
Evidence of active infection or serious infection (e.g., septic shock with multi-organ dysfunction) within the past month
Active unresolved infection
Active infection (any infection requiring treatment).
Active, unresolved infection
No evidence of active infection and no serious infection within the past month
Evidence of active infection, or serious infection within the past month
No evidence of active infection and no serious infection within the past month
Evidence of active infection, or serious infection within the past month
Active herpes simplex or herpes zoster. Subjects on prophylaxis for herpes who started taking medication at least 30 days prior to study entry, and have no active signs of active infection, and whose last active infection was more than 6 months ago, may enter the study, and should continue to take the prescribed medication for the duration of the study.
Current evidence of invasive fungal infection (blood or tissue culture); patients with recent fungal infection must have a subsequent negative cultures to be eligible; known HIV (new testing not required) or evidence of active hepatitis B or C infection (with rising transaminase values)
Active serious infection
Active infection
Known active infection, or major episode of infection within 4 week prior to the start of Cycle 1
Serious active infection or gastrointestinal disease
Active infection\r\n* Active infection includes patients with positive blood cultures
No active infection
Active systemic infection
Active infection that is not responding to antimicrobial therapy
Active and uncontrolled infection at time of transplantation including active infection with Aspergillus or other mold, or human immunodeficiency virus (HIV) infection
Active infection
Active systemic infection
Any evidence of serious active infection.
Known active systemic infection (Grade ?2).
No evidence of active infection and no serious infection within the past month
Evidence of active infection, or serious infection within the past month
Active, clinically serious infection greater than CTCAE grade 2. Patients may be eligible upon resolution of the infection.
Acute, active infection within 14 days of enrollment
Patients with active lung infection or active pulmonary edema
Active serious infection (pulmonary infiltrates or lesions are allowed only after the appropriate diagnostic testing is negative for infection or appropriate therapy was initiated for probable infection)
Concurrent, acute, active infection, or treatment for infection, other than oral thrush or genital herpes, within 14 days of enrollment
Active infection
No active infection
Infection:\r\n* Local infection at the puncture site\r\n* Systemic infection, osteomyelitis, discitis
Active infection
Concurrent active infection
Patients with active infection at time of biopsy
No active infection
Active infection.
Known active infection.
Infection
Active infection
Patients should not have any clinical evidence of an active infection at the time of enrollment
Patients with active pulmonary or pericardial infection
Known active infection
Evidence of active infection
Infection
Infection
A serious active infection (> grade 2) within 7 days of enrollment
Currently active infection
Active systemic, pulmonary, or pericardial infection
Documented or suspected infection
Active infection that is not responding to antimicrobial therapy
Active infection
Serious active infection at the time of pre-study screening.
Active infection
Active infection with hepatitis A, B, or C; active infection is defined as serologic positivity and elevated liver function tests
Active infection
Active lung infection
EXCLUSION - STUDY 1: Active infection
Active Infection
Active cutaneous infection or inflammation
Local or systemic infection
Patients must not have an active infection
Active systemic infection
Active infection at time of transplantation (including active infection with aspergillus or other mold within 30 days)
Active infection.
Active systemic infection or skin infection at or near the acupuncture sites
Clinically active infection; an active infection may alter the biodistribution of 18F-FLT
Evidence of active infection within 14 days of study enrollment
No active skin infection
Recognized concurrent active infection
Active infection
Active infection
Patients with active systemic, pulmonary, or pericardial infection
Patients that have recognized concurrent active infection
Active infection
Active infection
Active infection (any infection requiring treatment).
